Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
about
Tumor metastasis to boneMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerThe role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasisOsteoblasts Are the Centerpiece of the Metastatic Bone MicroenvironmentLow-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new boneRegulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells.BMP7: a new bone metastases prevention?BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells.A rapid and sensitive bioassay to measure bone morphogenetic protein activity.A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum.Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.Prostate cancer and bone: the elective affinities.Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.A review of osteocyte function and the emerging importance of sclerostinMethylation signature of lymph node metastases in breast cancer patientsThe search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression.Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesionNothing but skin and bone.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice.Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.Bone morphogenetic protein 4 (BMP-4) and epidermal growth factor (EGF) inhibit metalloproteinase-9 (MMP-9) expression in cancer cells.Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasisInsulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signalingBone-targeted agents in the treatment of lung cancer.The Wnt inhibitor dickkopf-1: a link between breast cancer and bone metastases.Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.ZEB1 Upregulates VEGF Expression and Stimulates Angiogenesis in Breast CancerHistone acetylation regulates prostate ductal morphogenesis through a bone morphogenetic protein-dependent mechanismInhibition of BMP signaling suppresses metastasis in mammary cancerCancer to bone: a fatal attraction.Bone morphogenetic protein 6 expression in oral cavity squamous cell cancer is associated with bone invasion.Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone.Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.Prostate cancer: the need for biomarkers and new therapeutic targets.Bone morphogenetic proteins and cancer: review of the literature.Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer.
P2860
Q21195416-DAE4491D-469A-45F1-92BC-763BC821D6B7Q27024775-A6179402-1AD8-42AF-83E2-E5128364804BQ27437809-B83B2B7E-61E4-4F4E-A5AE-1A0D8DB5B10BQ28077461-36C2D382-2D53-47AA-B013-0D88DE7E5374Q28593008-E244CE7E-FB20-4A95-9530-B97D52F02CBBQ30426736-2D3D8641-2032-4E76-8138-78FE23245A25Q30443506-87F07C32-BC6D-47A2-A415-6DDC4A2790BDQ30838242-81EB97C0-B676-41FE-B012-E7FE80AF98D2Q33299610-45D56388-D0BC-4F6A-8C4B-4CF2BB3B62C5Q33419686-121A847C-A470-4E16-9392-4CE631E1E4BDQ33705995-AC90DFC2-83EF-44D5-AD13-D7DC72A79AFEQ33748979-FF263033-3506-426C-9907-A71CC845A83DQ33757791-1AA171F5-ACA0-4718-9ED5-C686D7DAE61CQ34067118-1E064ECE-C814-4201-9DF6-8803ADE36B30Q34264395-8599F367-7392-46EE-83C4-9BD1EFE28EC9Q34303360-BF30D288-95DE-4094-9C68-6F171D4B80BEQ34403242-15939CAF-BAE4-4E1D-AA8C-B89413E4D433Q34574593-70EB378A-E52D-4868-9242-C47949B37813Q34576635-AEE882C2-2E32-4D28-BDBF-088C27E2E946Q34699785-E3E67FFE-B028-46E2-B6C0-C83B2CA14354Q34998432-54431AEF-63D4-4E2C-B3FC-3D71AC128239Q35087364-769F035A-F24D-4E2A-90AF-DE6B806BD76EQ35376245-E3C890B0-BAEC-40D7-8D35-AD5B5A3C9376Q35570431-2E878884-3FB9-425D-AE0B-C18DA880CF4CQ35609965-F5D30F20-A45F-44A2-86E6-7EFA3C5704D6Q35679829-E02B9054-B4BB-4BD4-9503-4D6CB16CA4ADQ35774487-A5DC3360-0BD4-4B3E-A833-2DF0C9AC9EB7Q35780792-70B163AE-3430-4E9E-BCA5-9556C792C2F3Q35792851-4BFA264C-A557-4ADF-8F44-A388A518CD97Q35840465-35F60884-199F-4AE0-8684-EA74175A58FDQ35925156-351C55EE-FBBB-4F8F-9088-433BD545237EQ36202684-FC186D29-09FA-48AF-BBCB-79619729F7FCQ36398681-96662344-2BA3-4ABD-A848-CD8050A46868Q36884628-732B1250-BBC6-41FB-B943-0B2066000765Q37248515-5A45CEF0-2BF9-458F-9D84-E92D443B053FQ37407566-714AE58F-8E0F-4D0F-91FE-134ED0BBEFD6Q37424118-A1B216CB-88D9-4668-A31D-5725BAA51A27Q37476043-2C460AD0-ED27-4EA5-A8C3-90F66D376625Q37665275-3F0B2CC2-8A23-45C2-9338-9AE0F2333185Q37732437-2FB8A378-E6E7-420F-9246-3B2E05E7E75A
P2860
Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Bone morphogenetic protein-6 p ...... ases through a dual mechanism.
@en
type
label
Bone morphogenetic protein-6 p ...... ases through a dual mechanism.
@en
prefLabel
Bone morphogenetic protein-6 p ...... ases through a dual mechanism.
@en
P2093
P1433
P1476
Bone morphogenetic protein-6 p ...... ases through a dual mechanism.
@en
P2093
P304
P356
10.1158/0008-5472.CAN-05-1891
P407
P50
P577
2005-09-01T00:00:00Z